|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cai QY, Yu P, Besch-Williford C, Smith CJ,
Sieckman GL, Hoffman TJ and Ma L: Near-infrared fluorescence
imaging of gastrin releasing peptide receptor targeting in prostate
cancer lymph node metastases. Prostate. 73:842–854. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Heidenreich A, Bastian PJ, Bellmunt J,
Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T,
Zattoni F, et al; European Association of Urology. EAU guidelines
on prostate cancer. part 1: Screening, diagnosis, and local
treatment with curative intent-update 2013. Eur Urol. 65:124–137.
2014. View Article : Google Scholar
|
|
4
|
Osborne JR, Akhtar NH, Vallabhajosula S,
Anand A, Deh K and Tagawa ST: Prostate-specific membrane
antigen-based imaging. Urol Oncol. 31:144–154. 2013. View Article : Google Scholar
|
|
5
|
Yi X, Wang F, Qin W, Yang X and Yuan J:
Near-infrared fluorescent probes in cancer imaging and therapy: An
emerging field. Int J Nanomed. 9:1347–1365. 2014. View Article : Google Scholar
|
|
6
|
Yang X, Shi C, Tong R, Qian W, Zhau HZ,
Wang R, Zhu G, Cheng J, Yang VW, Cheng T, et al: Near IR
heptamethine cyanine dye-mediated cancer imaging. Clin Cancer Res.
16:2833–2844. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jiang C, Cheng H, Yuan A, Tang X, Wu J and
Hu Y: Hydrophobic IR780 encapsulated in biodegradable human serum
albumin nanoparticles for photothermal and photodynamic therapy.
Acta Biomater. 14:61–69. 2015. View Article : Google Scholar
|
|
8
|
Wang Y, Liu T, Zhang E, Luo S, Tan X and
Shi C: Preferential accumulation of the near infrared heptamethine
dye IR-780 in the mitochondria of drug-resistant lung cancer cells.
Biomaterials. 35:4116–4124. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang X, Shao C, Wang R, Chu CY, Hu P,
Master V, Osunkoya AO, Kim HL, Zhau HE and Chung LW: Optical
imaging of kidney cancer with novel near infrared heptamethine
carbocyanine fluorescent dyes. J Urol. 189:702–710. 2013.
View Article : Google Scholar
|
|
10
|
Heidenreich A, Bastian PJ, Bellmunt J,
Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T,
Zattoni F, et al; European Association of Urology. EAU guidelines
on prostate cancer. Part II: Treatment of advanced, relapsing, and
castration-resistant prostate cancer. Eur Urol. 65:467–479. 2014.
View Article : Google Scholar
|
|
11
|
Hahn C, Song SH, Oh CH and Berini P:
Single-mode lasers and parity-time symmetry broken gratings based
on active dielectric-loaded long-range surface plasmon polariton
waveguides. Opt Express. 23:19922–19931. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Attard G, Reid AH and de Bono JS:
Abiraterone acetate is well tolerated without concomitant use of
corticosteroids. J Clin Oncol. 28:e560–561; author reply e562.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ryan CJ, Smith MR, Fong L, Rosenberg JE,
Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, et al:
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate
demonstrating clinical activity in patients with
castration-resistant prostate cancer who received prior
ketoconazole therapy. J Clin Oncol. 28:1481–1488. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Attard G, Reid AH, A'Hern R, Parker C,
Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, et
al: Selective inhibition of CYP17 with abiraterone acetate is
highly active in the treatment of castration-resistant prostate
cancer. J Clin Oncol. 27:3742–3748. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yin L and Hu Q: CYP17 inhibitors -
abiraterone, C17,20-lyase inhibitors and multi-targeting agents.
Nat Rev Urol. 11:32–42. 2014. View Article : Google Scholar
|
|
16
|
Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao
C, Murphy CF, Yang H, Zhau HE, Balian G and Chung LW: Establishing
human prostate cancer cell xenografts in bone: Induction of
osteoblastic reaction by prostate-specific antigen-producing tumors
in athymic and SCID/bg mice using LNCaP and lineage-derived
metastatic sublines. Int J Cancer. 77:887–894. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yi X, Zhang G and Yuan J: Renoprotective
role of fenoldopam pretreatment through hypoxia-inducible
factor-1alpha and heme oxygenase-1 expressions in rat kidney
transplantation. Transplant Proc. 45:517–522. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang C, Liu T, Su Y, Luo S, Zhu Y, Tan X,
Fan S, Zhang L, Zhou Y, Cheng T, et al: A near-infrared fluorescent
heptamethine indocyanine dye with preferential tumor accumulation
for in vivo imaging. Biomaterials. 31:6612–6617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu W, Peck EM, Hendzel KD and Smith BD:
Sensitive structural control of macrocycle threading by a
fluorescent squaraine dye flanked by polymer chains. Org Lett.
17:5268–5271. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hellebust A and Richards-Kortum R:
Advances in molecular imaging: Targeted optical contrast agents for
cancer diagnostics. Nanomedicine (Lond). 7:429–445. 2012.
View Article : Google Scholar
|
|
21
|
Yue C, Liu P, Zheng M, Zhao P, Wang Y, Ma
Y and Cai L: IR-780 dye loaded tumor targeting theranostic
nanoparticles for NIR imaging and photothermal therapy.
Biomaterials. 34:6853–6861. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang E, Luo S, Tan X and Shi C:
Mechanistic study of IR-780 dye as a potential tumor targeting and
drug delivery agent. Biomaterials. 35:771–778. 2014. View Article : Google Scholar
|
|
23
|
Sternberg CN, Castellano D, Daugaard G,
Géczi L, Hotte SJ, Mainwaring PN, Saad F, Souza C, Tay MH, Garrido
JM, et al; Abiraterone Global EAP Investigators. Abiraterone
acetate for patients with metastatic castration-resistant prostate
cancer progressing after chemotherapy: Final analysis of a
multi-centre, open-label, early-access protocol trial. Lancet
Oncol. 15:1263–1268. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Richards J, Lim AC, Hay CW, Taylor AE,
Wingate A, Nowakowska K, Pezaro C, Carreira S, Goodall J, Arlt W,
et al: Interactions of abiraterone, eplerenone, and prednisolone
with wild-type and mutant androgen receptor: A rationale for
increasing abiraterone exposure or combining with MDV3100. Cancer
Res. 72:2176–2182. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Antonarakis ES, Lu C, Wang H, Luber B,
Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, et
al: AR-V7 and resistance to enzalutamide and abiraterone in
prostate cancer. N Engl J Med. 371:1028–1038. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Matsubara N, Uemura H, Satoh T, Suzuki H,
Nishiyama T, Uemura H, Hashine K, Imanaka K, Ozono S and Akaza H: A
phase 2 trial of abiraterone acetate in Japanese men with
metastatic castration-resistant prostate cancer and without prior
chemotherapy (JPN-201 study). Jpn J Clin Oncol. 44:1216–1226. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Murga JD, Moorji SM, Han AQ, Magargal WW,
DiPippo VA and Olson WC: Synergistic co-targeting of
prostate-specific membrane antigen and androgen receptor in
prostate cancer. Prostate. 75:242–254. 2015. View Article : Google Scholar
|
|
28
|
Kosaka T, Miyajima A, Yasumizu Y, Miyazaki
Y, Kikuchi E and Oya M: Limited in vitro efficacy of CYP17A1
inhibition on human castration resistant prostate cancer. Steroids.
92:39–44. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shan L: Near-infrared fluorescence
1,1-dioctadecyl-3,3,3,3-tetra-methylindotricarbocyanine iodide
(DiR)-labeled macrophages for cell imaging. Molecular Imaging and
Contrast Agent Database. MICAD; Bethesda, MD: 2004
|
|
30
|
Shao C, Liao CP, Hu P, Chu CY, Zhang L,
Bui MH, Ng CS, Josephson DY, Knudsen B, Tighiouart M, et al:
Detection of live circulating tumor cells by a class of
near-infrared heptamethine carbocyanine dyes in patients with
localized and metastatic prostate cancer. PLoS One. 9:e889672014.
View Article : Google Scholar : PubMed/NCBI
|
